ANI Pharmaceuticals (ANIP) VP sells 500 shares under 10b5-1 plan

Rhea-AI Filing Summary

ANI Pharmaceuticals senior vice president, general counsel and secretary Meredith Cook reported an open-market sale of 500 shares of Common Stock. The shares were sold at an average price of $82.03 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. After this sale, Cook directly held 77,890 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary 10b5-1

Net Seller: 500 shares ($41,015)

Net Sell 1 txn

Insider Cook Meredith

Role SR. VP, GENERAL COUNSEL & SEC.

Sold 500 shs ($41K)

Type	Security	Shares	Price	Value
Sale	Common Stock	500	$82.03	$41K

Holdings After Transaction: Common Stock — 77,890 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 500 shares Sale price: $82.03 per share Shares held after transaction: 77,890 shares +1 more

4 metrics

Shares sold 500 shares Open-market sale of Common Stock

Sale price $82.03 per share Average price for 500 shares sold

Shares held after transaction 77,890 shares Direct ownership following sale

Trading plan adoption date September 15, 2025 Rule 10b5-1 plan governing the sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		S(1)		500	D	$82.03	77,890	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

Remarks:

	/s/ Meredith W. Cook	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Meredith Cook?

ANI Pharmaceuticals reported that Meredith Cook executed an open-market sale of 500 shares of Common Stock. She is the senior vice president, general counsel and secretary, and this transaction reflects a small adjustment to her direct equity holdings in the company.

At what price were Meredith Cook’s ANI Pharmaceuticals shares sold?

The 500 ANI Pharmaceuticals shares were sold at an average price of $82.03 per share. This price represents the execution level for the open-market transaction disclosed, providing investors a clear view of the value realized in this specific insider sale.

How many ANI Pharmaceuticals shares does Meredith Cook hold after the sale?

Following the reported transaction, Meredith Cook directly holds 77,890 shares of ANI Pharmaceuticals Common Stock. This post-transaction balance shows she maintains a substantial continuing equity position in the company despite the relatively small sale disclosed.

Was Meredith Cook’s ANI Pharmaceuticals share sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected under a Rule 10b5-1 trading plan adopted on September 15, 2025. Such pre-arranged plans schedule trades in advance, helping separate routine portfolio management from discretionary timing decisions by insiders.

Is Meredith Cook’s ANI Pharmaceuticals transaction classified as a buy or a sell?

The transaction is classified as a sell, specifically an open-market sale of Common Stock. The Form 4 identifies it with transaction code “S” and describes it as a sale in open market or private transaction, reducing her share count by 500 shares.